DWP 17061
Alternative Names: DWP-17061; iN1011-N17Latest Information Update: 28 Nov 2023
At a glance
- Originator Daewoong Pharmaceutical
- Developer Daewoong Pharmaceutical; iN Therapeutics
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Musculoskeletal pain; Postherpetic neuralgia
Most Recent Events
- 18 Nov 2023 DWP 17061 is still in phase I trial for Musculoskeletal pain (In volunteers) in Australia (PO, Capsule) (NCT05496205) (ACTRN12620001253998)
- 08 Oct 2023 iN Therapeutics completes a phase I trial in Musculoskeletal pain (In volunteers) in Australia (PO, Capsule) (NCT05496205) (ACTRN12620001253998)
- 11 Nov 2022 Phase-I clinical trials in Postherpetic neuralgia in Australia (PO) (NCT06218784)